A1 - From bench to bedside: advancing pharmaceutical care


Organised by the FIP Programme Committee


Hiroshi Suzuki (FIP Programme Committee, Japan) and Michael Ward (FIP Programme Committee, Australia)


Recent development of science and technology has promoted pharmacotherapy.  However, in order to obtain the best outcome, development of individualised therapy is required. In this session, by taking the examples of the pharmacotherapy of cancer, infectious diseases, and Alzheimer’s disease and drug-induced toxicity, recent advances in individualised medicine are introduced. We will discuss how pharmacists can contribute to individualised therapy.


14:30 – 14:40  Introduction by the chairs

15:50 – 16:10 Coffee/tea break

  1. 14:40 – 15:15 Efficient tumour therapy depending on the characteristics of cancer cells
    Sabrina Arena (University of Torino, Italy)
  1. 15:15 – 15:50 Analysis of drug-induced toxicity
    Raul Andrade (University of Málaga, Spain)
  1. 16:10 – 16:45 Suitable utilisation of antibiotics to avoid the appearance of drug-resistant bacteria
    Jodi Lindsay (University of London, UK)
  1. 16:45 – 17:20 Disease progression and suitable pharmacotherapy
    Nick Holford (University of Auckland, New Zealand)

17:20 – 17:30  Conclusion by the chairs

Learning Objectives

At the end of this session, participants will be able to:
  1. Adopt the suitable utilisation of molecular targeted drugs depending on the characteristics of tumours;
  2. Evaluate the classification of patients in terms of pharmacological response in the initial process for safe and efficient drug treatment;
  3. Demonstrate the importance of suitable utilisation of antibiotics by learning how bacteria acquire resistance in patients;
  4. Investigate how the concept of PPK is expanded to predict disease progression and drug effects.
Type of session: Application-based